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PCoronary Artery Disease
Determinants of Progression of
Coronary Artery Calcification in Type 2 Diabetes
Role of Glycemic Control and
Inflammatory/Vascular Calcification Markers
Dhakshinamurthy Vijay Anand, MBBS, MRCP,*† Eric Lim, MBCHB, MA, MRCP,*
Daniel Darko, MD, MRCP,‡ Paul Bassett, MSC,§ David Hopkins, BSC, MBCHB, FRCP,
David Lipkin, BSC, MD, FRCP,*¶ Roger Corder, PHD, MRPHARMS,†
Avijit Lahiri, MBBS, MSC, MRCP, FACC, FESC*
London, United Kingdom
Objectives This study prospectively evaluated the relationship between cardiovascular risk factors, selected biomarkers
(high-sensitivity C-reactive protein [hs-CRP], interleukin [IL]-6, and osteoprotegerin [OPG]), and the progression of
coronary artery calcification (CAC) in type 2 diabetic subjects.
Background Coronary artery calcification is pathognomonic of coronary atherosclerosis. Osteoprotegerin is a signaling molecule
involved in bone remodeling that has been implicated in the regulation of vascular calcification and atherogenesis.
Methods Three hundred ninety-eight type 2 diabetic subjects without prior coronary disease or symptoms (age 52  8
years, 61% male, glycated hemoglobin [HbA1c] 8  1.5) were evaluated serially by CAC imaging (mean
follow-up 2.5  0.4 years). Progression/regression of CAC was defined as a change 2.5 between the square root
transformed values of baseline and follow-up volumetric CAC scores. Demographic data, risk factors, glycemic con-
trol, medication use, serum hs-CRP, IL-6, and plasma OPG levels were measured at baseline and follow-up.
Results Two hundred eleven patients (53%) had CAC at baseline. One hundred eighteen patients (29.6%) had CAC pro-
gression, whereas 3 patients (0.8%) had regression. Age, male gender, hypertension, baseline CAC, HbA1c 7,
waist-hip ratio, IL-6, OPG, use of beta-blockers, calcium channel antagonists, angiotensin-converting enzyme
(ACE) inhibitors, statins, and Framingham/UKPDS (United Kingdom Prospective Diabetes Study) risk scores were
univariable predictors of CAC progression. In the multivariate model, baseline CAC (odds ratio [OR] for CAC
400  6.38, 95% confidence interval [CI] 2.63 to 15.5, p  0.001), HbA1c 7 (OR 1.95, CI 1.08 to 3.52, p 
0.03), and statin use (OR 2.27, CI 1.38 to 3.73, p  0.001) were independent predictors of CAC progression.
Conclusions Baseline CAC severity and suboptimal glycemic control are strong risk factors for CAC progression in type 2 dia-
betic subjects. (J Am Coll Cardiol 2007;50:2218–25) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.032s
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eoronary artery calcification (CAC) is pathognomic of coro-
ary atherosclerosis. In recent years, there has been consider-
ble interest in CAC for several reasons. It is a characteristic
hat can be noninvasively and reproducibly quantified at a
opulation level. Furthermore, multiple large cross-
rom the *Cardiac Imaging and Research Centre, Wellington Hospital, London,
nited Kingdom; †William Harvey Research Institute at Barts and the London,
ueen Mary’s School of Medicine and Dentistry, London, United Kingdom;
Department of Endocrinology, Central Middlesex Hospital, London, United
ingdom; §Stats Consultancy, London, United Kingdom; Department of Endocri-
ology, Kings College Hospital, London, United Kingdom; and the ¶Department of
ardiology, Royal Free Hospital, London, United Kingdom. This study was
upported by the Derrick Smith/Harrow Cardiovascular Trust research grant.b
Manuscript received February 19, 2007; revised manuscript received August 23,
007, accepted August 27, 2007.ectional and prospective studies have confirmed that it can
e treated as an independent risk factor for improving
ardiovascular risk prediction beyond that provided by
onventional risk factors (1–3). More recently, some studies
uggest that serial assessment of CAC scores might be
elpful in monitoring the evolution of coronary atheroscle-
otic plaque and assessing the effectiveness of medical
herapies for reducing cardiovascular risk (4).
Type 2 diabetes is associated with accelerated atheroscle-
osis and considered to be a coronary heart disease (CHD)
quivalent (5). Experimental, histopathological, and clinical
tudies have shown that it affects the process of atherogen-
sis at multiple levels, increasing the risk of atherothrom-
otic clinical sequelae (6). At this time, however, there are
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atient subgroup. However, recent data suggest that there is
substantial prevalence of CAC, even in type 2 diabetic
ubjects who are asymptomatic (7,8), and that CAC predicts
oth abnormal myocardial perfusion and incident cardiovascu-
ar disease.
In this article, we provide the first prospective report of
he progression of CAC specifically in type 2 diabetic
ubjects without prior CHD or symptoms at baseline.
dditionally, we report on the association between both
stablished cardiovascular risk factors as well as 3 selected
iomarkers (high-sensitivity C-reactive protein [hs-CRP], in-
erleukin [IL]-6, and osteoprotegerin [OPG]) and the pro-
ression of CAC. High-sensitivity CRP and IL-6 are
arkers of systemic inflammation, whereas OPG is a
ignaling molecule involved in bone remodeling that has
ecently been implicated in the regulation of vascular calci-
cation and atherogenesis (9). Osteoprotegerin is a member
f the tumor necrosis factor superfamily that functions as a
ecoy receptor for the receptor activator of nuclear factor-
appa beta ligand preventing osteoclast activation/bone
esorption (10). Osteoprotegerin is upregulated in calcified
oronary plaques (11). Plasma OPG measurements have
een correlated with angiographic disease severity and
ardiovascular events independent of conventional risk fac-
ors in recent publications (12,13).
ethods
he study was approved by the local institutional ethics
eview committees, and all subjects provided written in-
ormed consent.
atients. This is a planned extension of a prospective study
f type 2 diabetic subjects without prior CHD that we have
reviously reported. In brief, 510 asymptomatic patients
ith type 2 diabetes were enrolled between August 2002
nd February 2004. Study participants were recruited from
diabetes clinics in secondary care (Northwick Park and
entral Middlesex Hospitals, London, United Kingdom).
nclusion criteria were: 1) type 2 diabetes 1 year duration;
nd 2) age between 30 and 65 years. Exclusion criteria were:
) typical angina pectoris or anginal equivalent symptoms
uch as dyspnea on exertion; 2) history of positive stress test,
yocardial infarction, heart failure, or coronary revascular-
zation; 3) electrocardiographic evidence of Q-wave myo-
ardial infarction, ischemic ST-segment or T-wave changes,
r complete left bundle branch block; 4) prior history of
eripheral vascular disease, intermittent claudication, stroke,
r transient ischemic attack; and 5) renal impairment
creatinine 1.4 mg/dl) or serious life threatening illnesses.
revalence of CAC was determined in this baseline cohort
ith electron beam computed tomography (EBCT). As part
f the current study, subjects were then asked to attend for
follow-up assessment similar to the baseline study. In view
f difficulties in accurately estimating progression of CAC
n the presence of intracoronary stents and metallic clips osed in coronary artery bypass
rafting, patients who were re-
ascularized in the intervening
eriod were excluded from
ollow-up imaging. All other
ubjects were el igible for
articipation.
easurements. CLINICAL AS-
ESSMENT. Demographic data,
isk factors, microvascular dis-
ase, medication use, body mass
ndex (BMI), waist/hip ratio
WHR), blood pressure, and the
redicted 10-year absolute coro-
ary heart disease risk based on
he Framingham risk function
14) and UKPDS (United King-
om Prospective Diabetes Study)
isk engine (15) were recorded at
ollow-up with the same meth-
ds as the baseline assessment.
IOCHEMICAL MEASUREMENTS.
lood was drawn to determine
CCT (Diabetes Control and Complications Trial) aligned
lycated hemoglobin (HbA1c), lipid profile, urea, and creati-
ine. Serum hs-CRP (ICN Pharmaceuticals, Orangeburg,
ew York), IL-6 (R&D Systems Inc., Minneapolis, Minne-
ota), and plasma OPG levels (Biomedica, Vienna, Austria)
16) were measured by enzyme-linked immunosorbent assay
ELISA). Intra-assay and interassay coefficients of variation for
s-CRP, IL-6, and OPG measurements were 3.3% and 3.7%,
.4% and 7.8%, and 5% and 7.5%, respectively. Urine samples
ere also obtained to determine the urine albumin/creatinine
atio.
AC IMAGING. The EBCT scanner that was used in the
aseline study was employed in this follow-up study to
educe interstudy variability (GE Imatron C-150, San
rancisco, California). The same operators and workstation
ere also used. In brief, 40 contiguous 3-mm slices were
btained during a single breath-hold starting at the carina
nd proceeding to the level of the diaphragm. Scan time was
00 ms/slice, synchronized to 40% of the R-R interval.
gatston and volumetric calcium scores were calculated to
uantify the extent of CAC by a single experienced inves-
igator blinded to the clinical data on an Aquarius worksta-
ion (TeraRecon Inc., San Mateo, California). For deter-
ining progression, volumetric CAC scores were used in
iew of their superior reproducibility (17). The CAC scores
ere classified into 4 categories on the basis of their severity:
to 10 mm3 (minimal), 11 to 100 mm3 (mild), 101 to 400
m3 (moderate), and 400 mm3 (severe).
tatistical analysis. Analyses were carried out with
TATA version 8 (Stata Corp. LP, College Station, Texas)
Abbreviations
and Acronyms
CAC  coronary artery
calcification
CHD  coronary heart
disease
CI  confidence interval
EBCT  electron beam
computed tomography
HbA1c  glycated
hemoglobin
hs-CRP  high-sensitivity
C-reactive protein
IL  interleukin
IQR  interquartile range
LAD  left anterior
descending coronary artery
LDL  low-density
lipoprotein
OPG  osteoprotegerin
OR  odds ratior SPSS version 12.0 (SPSS Inc., Chicago, Illinois). Con-
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Determinants of CAC Progression in Diabetes December 4, 2007:2218–25inuous variables were summarized as mean  SD or
edian  interquartile range (IQR). Variables were exam-
ned for a linear relationship with progression of CAC and
ategorized if necessary. Continuous variables were com-
ared by the Mann-Whitney U test and categorical variables
y the chi-square test. Bivariate correlations between bio-
arker values and extent of CAC were performed with
pearman rank correlation. A p value 0.05 (2-sided) was
onsidered statistically significant.
EFINITION OF PROGRESSION OF CAC. A square root trans-
ormation of the baseline and follow-up volumetric CAC
easurements was made to stabilize the variance across all
anges of CAC (18). Significant progression/regression of
AC was defined as a change2.5 between the square root
ransformed values of baseline and follow-up volumetric
oronary calcium scores, because a change exceeding this
agnitude most likely represents a real change in CAC
ather than interscan variability.
Demographic and other clinical/laboratory variables of
nterest were then evaluated in a univariable logistic regres-
ion model to determine their relationship to progression of
AC. A backward selection procedure was applied to
dentify candidate variables for the multivariable model.
andidate variables included, from the pool of historical
isk factors and laboratory variables, those univariable pre-
ictors with p  0.2. For the multivariable model, only
hose variables with a p  0.05 were retained for the final
ariable selection.
esults
atients. Five hundred ten subjects were enrolled as part of
he baseline study. Four patients died during follow-up
median volumetric CAC score  961 [IQR: 531 to 3,481;
ange: 316 to 4,201 mm3]). Sixteen subjects underwent
oronary revascularization (median CAC  680 [IQR: 314
o 1,324; range: 42 to 3,056 mm3]) and were excluded from
ollow-up imaging. Of the remaining 490 subjects, 402
ttended and completed the follow-up evaluation (response
ate 82%). Table 1 summarizes the characteristics of those
atients who returned for follow-up imaging versus those
ho did not. Apart from lower serum triglyceride and IL-6
evels in patients who returned for follow-up imaging, no
ther statistically significant differences were seen. Image
uality was suboptimal in 4 patients, owing to breathing
rtefacts, and they were excluded from further analysis.
ean follow-up interval was 2.5 0.4 years. Mean age was
2  8 years, and 61% were men. Baseline and follow-up
haracteristics of the study population and details regarding
edical therapy are outlined in Table 2. There was a high
roportion of South Asians (n 217 [54%]) compared with
aucasians (n  82 [21%]) and Afro-Caribbeans (n  88
22%]), due to the geographical location of the study
opulation and the high prevalence of type 2 diabetes in
outh Asians (Table 3). Among those who underwent
ollow-up imaging, 8 patients (median CAC at baseline  p91 [IQR 313 to 1,029; range 41 to 1,345 mm3]) were
ospitalized with either unstable angina or acute myocardial
nfarction during the follow-up period.
istribution of CAC. One hundred eighty-seven patients
47%) had no CAC at baseline. The severity of CAC was
inimal in 36 patients (9%), mild in 93 patients (23%),
oderate in 55 patients (14%), and severe in 27 patients
7%). Table 4 compares the distribution of patients in
olumetric CAC score categories (No CAC, minimal [1 to
0], mild [11 to 100], moderate [101 to 400], severe [401 to
,000], and extensive [1,000] CAC) at baseline and
ollow-up and illustrates the number of patients who actu-
lly shifted risk categories during the course of the study.
elationship between biomarkers and CAC severity at
aseline/follow-up. At baseline, plasma OPG measure-
ents were correlated with the extent of CAC (r  0.32,
 0.0001). In contrast, serum hs-CRP and IL-6 were not
elated to atherosclerotic plaque burden (r  0.02, p  NS
or hs-CRP, and r  0.09, p  0.03 for IL-6). The OPG
easurements were related to CAC burden similarly at
ollow-up (r  0.24, p  0.001).
rogression of CAC. Mean CAC score change/year of
ollow-up was 16.1 (SD: 44.8) mm3. Progression of CAC
as observed in 118 patients (29.6%), whereas significant
egression was seen only in 3 subjects (0.8%). Progression
as most frequent in those with pre-existing CAC (Fig.
A). Among those with no calcification at baseline, pro-
ression was relatively infrequent (12%, 22 patients). The
bsolute change in CAC was small in those with little
haracteristics of Patients Who Attendedollow-Up Imaging Versus Those Who Did Not
Table 1 Characteristics of Patients Who AttendedFollow-Up Imaging Versus Those Who Did Not
Characteristic
Did Not
Attend
(n  88)
Attended
Follow-Up
(n  402) p Value
Age (yrs) 53 (9)* 52 (8)* 0.36
Male gender (%) 48 (55%) 244 (61%) 0.23
Baseline volumetric CAC (mm3) 0 (0–93.9)† 3.4 (0–57.9)† 0.87
Mean HbA1c (%) 8.4 (1.7)* 8.1 (1.5)* 0.24
Mean total cholesterol (mg/dl) 191 (43)* 187 (35)* 0.07
Mean LDL cholesterol (mg/dl) 109 (34)* 105 (31)* 0.22
Mean HDL cholesterol (mg/dl) 47 (11)* 51 (16)* 0.12
Mean triglycerides (mg/dl) 195 (142)* 160 (89)* 0.002
hs-CRP (mg/l) 5.4 (1.7–8.5)† 4.2 (1.8–7.8)† 0.37
IL-6 (pg/ml) 2.6 (1.2–4)† 1.9 (1.2–3)† 0.01
OPG (pmol/l) 6.8 (5.3–11.6)† 6.6 (4.6–10.3)† 0.36
Current smoker (%) 18 (20%) 75 (19%) 0.93
BP 140/90 mm Hg or
antihypertensive therapy (%)
64 (73%) 300 (75%) 0.40
BMI (kg/m2) 28.9 (5)* 28.5 (5.1)* 0.49
WHR 0.95 (0.08)* 0.94 (0.07)* 0.14
Duration of diabetes (yrs) 8.3 (7)* 7.9 (6)* 0.53
Statin therapy (%) 32 (36%) 153 (38%) 0.80
Mean (SD); †median (interquartile range).
BMI  body mass index; BP  blood pressure; CAC  coronary artery calcification; HbA1c 
lycated hemoglobin; HDL high-density lipoprotein; hs-CRP high-sensitivity C-reactive protein;
L  interleukin; LDL  low-density lipoprotein; OPG  osteoprotegerin; WHR  waist/hip ratio.re-existing CAC but much greater in those with signifi-
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*Median (interquartile range); †mean (SD).
ACE  angiotensin-converting enzyme; AT2  angiotensin 2; other abbrevi
BP
Abbreviations as in Table 1.
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December 4, 2007:2218–25 Determinants of CAC Progression in Diabetesant pre-existing CAC (Fig. 1B). Lesions in the left anterior
escending coronary artery (LAD) were more likely to
rogress (median [IQR] change in volumetric score in
AD: 28.8 [56] mm3, in comparison with 0 [0], 8.7 [31],
nd 15.3 [47] mm3 in the left main stem, left circumflex,
nd right coronary arteries, respectively [p  0.0001]).
atients with numerous calcified lesions were more likely to
rogress (43 [72%] patients with 5 lesions in the LAD
emonstrated CAC progression in comparison with 75
41.4%] of those with 5 lesions in LAD [p  0.004]).
Table 3 summarizes the baseline characteristics of sub-
ects who demonstrated progression of CAC compared with
hose who did not. One hundred fifty-seven subjects did not
ave CAC at either the baseline or follow-up evaluation.
igure 2 illustrates the absolute changes in CAC scores
etween the baseline and follow-up evaluation in the re-
aining 241 subjects. Thirty subjects (16%) without base-
ine CAC progressed to minimal/mild CAC categories at
ollow-up, as shown in Table 4. No statistically significant
ifferences were seen in risk-factor profiles/biochemical
arameters between those patients who progressed from a 0
aseline CAC score and those who did not. Among those
ith minimal baseline CAC, 25 subjects (70%) progressed
o mild/moderate CAC categories, whereas 2 subjects had a
egression of CAC score to 0. Twenty-one subjects (23%)
ith mild baseline CAC progressed similarly to moderate/
evere CAC categories at follow-up, whereas regression to
jects
f Study Subjects
line Follow-Up
13 (0–111.2)*
8 (1.3)†
(160–207)* 175 (31)/176 (152–195)*
(87–125)* 97 (27)†/97 (76–113)*
(40–55)* 51 (12)†/49 (42–58)*
(93–196)* 151 (116)†/123 (82–189)*
199 (50%)
229 (58%)
31 (8%)
87 (22%)
267 (66%)
17 (4%)
44 (11%)
79 (20%)
183 (46%)
43 (11%)
29.4 (6.5)†
0.95 (0.07)†
2.1 (1.1–5.1)*
NA
)* 5.9 (4.1–8.2)*
96 (24%)
76 (19%)
67 (17%)
ations as in Table 1.Baseline and Follow-Up Characteristics of Study Sub
Table 2 Baseline and Follow-Up Characteristics o
Variable Base
Volumetric CAC score (mm3) 3.4 (0–57.9)*
Mean HbA1c (%) 8.1 (1.5)†
Total cholesterol (mg/dl) 187 (35)†/183
LDL cholesterol (mg/dl) 105 (31)†/105
HDL cholesterol (mg/dl) 51 (16)†/47
Triglycerides (mg/dl) 160 (89)†/142
Statin therapy (%) 153 (38%)
Antihypertensive therapy (%) 194 (49%)
Insulin alone (%) 31 (8%)
Insulin  oral agent (%) 55 (14%)
Oral agent (%) 288 (71%)
Diet therapy (%) 28 (7%)
Beta-blocker therapy (%) 30 (8%)
Calcium channel antagonist (%) 72 (18%)
ACE inhibitor/AT2 antagonist (%) 152 (38%)
Current smoker (%) 75 (19%)
BMI (kg/m2) 28.5 (5.1)†
WHR 0.94 (0.07)†
hs-CRP (mg/l) 4.2 (1.8–7.8)*
IL-6 (pg/ml) 1.9 (1.2–3)*
OPG (pmol/l) 6.6 (4.6–10.3
Retinopathy (%) 88 (22%)
Peripheral neuropathy (%) 73 (18%)
Microalbuminuria (%) 60 (15%)aseline Characteristics ofrogressors/Nonp ogre s rs
Table 3 Baseline Characteristics ofProgressors/Nonprogressors
Variable
Progressors
(n  118)
Nonprogressors
(n  277)
Age (yrs) 54 (7.4) 52 (8.6)
Gender (% male) 67.8% 58.1%
Diabetes duration (yrs) 8 (4.9) 7.7 (5.8)
Systolic/diastolic BP (mm Hg) 140 (16)/85 (12) 135 (16)/83 (12)
Antihypertensive therapy (%) 72 (61%) 120 (43%)
Ever a smoker/current smoker (%) 41%/22% 38%/18%
BMI (kg/m2) 28.6 (5.3) 28.5 (5)
WHR 0.95 (0.08) 0.93 (0.07)
Total cholesterol (mg/dl) 187 (35) 187 (35)
LDL cholesterol (mg/dl) 105 (27) 105 (31)
HDL cholesterol (mg/dl) 51 (14) 51 (20)
Triglycerides (mg/dl) 159 (98) 160 (89)
Statin therapy (%) 56 (47%) 96 (35%)
HbA1c (%) 8.1 (1.3) 8.1 (1.6)
Glycemic control (HbA1c 7%) 86 (73%) 204 (74%)
Median volumetric CAC at baseline 58.8 (6–215.2) 0 (0–20)
Baseline volumetric CAC 0 96 (81.4%) 112 (40%)
Ethnicity (%)
Caucasian 26 (22%) 56 (20%)
South Asian 80 (68%) 137 (49%)
Afro-Caribbean 10 (8%) 78 (28%)
Other 2 (2%) 9 (3%)inimal CAC was seen in 1 subject. Ten subjects (18%)
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Determinants of CAC Progression in Diabetes December 4, 2007:2218–25ith moderate baseline CAC and 5 subjects (31%) with
evere baseline CAC progressed to severe and extensive
AC categories, respectively, at follow-up. None of the
ubjects with moderate/severe baseline CAC regressed to
ower CAC categories.
Age (odds ratio [OR] 1.40, 95% confidence interval [CI]
.07 to 1.84, p  0.02); hypertension (OR 1.85, 95% CI
.08 to 3.17, p 0.03); baseline HbA1c7 (OR 1.84, 95%
I 1.09 to 3.13, p  0.02); baseline volumetric CAC score
OR for CAC 400 mm3  8.09, 95% CI 3.46 to 18.9, p
0.001); serum IL-6 (OR for log IL-6  1.71, 95% CI
.02 to 2.9, p  0.05); plasma OPG (OR for plasma OPG
9 pg/ml  2.5, 95% CI 1.39 to 4.10, p  0.004); use of
tatins (OR for statin-treated patients with low-density
ipoprotein [LDL] cholesterol100 mg/dl 3.12, 95% CI
.89 to 5.15, p  0.001); beta-blockers (OR 2.18, 95% CI
.15 to 4.42, p  0.02); calcium channel antagonists (OR
.26, 95% CI 1.36 to 3.76, p  0.02); and angiotensin-
onverting enzyme inhibitors/angiotensin receptor blockers
OR 1.6, 95% CI 1.02 to 2.5, p  0.04), Framingham (OR
.43, CI 1.03 to 1.98, p  0.03), and UKPDS risk scores
OR 1.78, 95% CI 1.27 to 2.47, p 0.001) were univariable
redictors of CAC progression.
Fifty-six percent of the study participants (n  221) were
reated with statins either at baseline or during the
Figure 1 Relationship Between Baseline CAC Severity and CAC
(A) Progression of coronary calcium according to baseline coronary artery calcifica
parentheses. (B) Median change in volumetric CAC score (mm3) according to base
Distribution of Volumetric CAC Scores at Baseli
Table 4 Distribution of Volumetric CAC Sco
Baseline
Volumetric CAC, mm3
Fo
0 1–10
0 157 (84%)* 16 (9%)
1–10 2 (5%) 9 (25%)
11–100 0 1 (1%)
101–400 0 0
401–1,000 0 0
1,000 0 0
*Percentages are quoted for each coronary artery calcification (CAC)ollow-up period. The relationship between statin use and
ollow-up lipid levels, hs-CRP, and OPG is shown in
able 5. Despite achieving lower lipid levels at follow-up,
tatin-treated patients had a greater degree of CAC pro-
ression (% of patients with progression  38% [n  85],
bsolute CAC score change/year  25 [SD: 55] mm3) in
omparison with untreated patients (% of patients with
rogression  19% [n  33], absolute CAC change/year  6
SD: 23] mm3). In the final multivariate analysis, baseline
AC (OR for CAC400 mm3 6.38, 95% CI 2.63 to 15.5,
 0.001), HbA1c 7 (OR 1.95, 95% CI 1.08 to 3.52, p 
.03), and statin use (OR 2.27, 95% CI 1.38 to 3.73, p 
.001) were independent predictors of CAC progression
Fig. 3).
Of the 8 patients who sustained an acute cardiac event
uring follow-up, 4 demonstrated CAC progression. We
erformed logistic regression analyses after reclassifying all
atients who sustained an acute cardiac event during
ollow-up as “progressors.” Male gender (OR 1.58, 95% CI
.01 to 2.47, p  0.05) and waist-hip ratio (OR [for 0.1-U
ncrease] 1.4, 95% CI 1.04 to 1.87, p  0.03) were
dditional univariable predictors of progression in this
nalysis. However, no significant changes were observed in
he results of final multivariate analysis.
ression
AC) severity. The number of patients with CAC progression is shown in
AC severity. The error bars represent interquartile ranges (IQRs). FU  follow-up.
d Follow-Up
t Baseline and Follow-Up
p Volumetric CAC Score, mm3
1–100 101–400 401–1,000 >1,000
4 (7%) 0 0 0
4 (67%) 1 (3%) 0 0
1 (76%) 20 (22%) 1 (1%) 0
0 45 (82%) 10 (18%) 0
0 0 11 (69%) 5 (31%)
0 0 0 16
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ackground and previous work. We have previously re-
orted on the prevalence and predictors of CAC in type 2
iabetic subjects without prior CHD (7). In that report, we
erified that majority of the established risk factors (age, male
ender, blood pressure, smoking, hyperlipidemia, waist-hip
atio) as well as duration of diabetes, presence of retinopathy,
tatin use, white race/ethnicity, and Framingham/UKPDS risk
cores were univariable predictors of CAC. As part of this
revious work, we also evaluated 3 selected biomarkers of
nflammation/vascular calcification (hs-CRP, IL-6, and
lasma OPG) (19). Neither hs-CRP nor IL-6 were predic-
ive of prevalent CAC (baseline CAC score). In contrast,
lasma OPG was a powerful predictor of prevalent CAC
OR 3.08, 95% CI 2.42 to 3.92, p  0.001).
ey findings of the present study. The current report
xtends our previous work by examining the factors predict-
ng progression of CAC (follow-up: 2.5 years) in the same
opulation. We found that progression was frequent
29.6%), particularly in those with pre-existing CAC. Con-
Figure 2 Absolute Changes in CAC Scores
Between the Baseline and Follow-Up Evaluation
Absolute changes in coronary artery calcification (CAC) scores between the
baseline and follow-up evaluation in 241 patients. The remaining 157 patients
did not have calcification at the baseline and follow-up evaluation.
Relationship Between Statin Use and Biochemic
Table 5 Relationship Between Statin Use an
Parameter
Untreated Patients (n 
Baseline Follo
Total cholesterol (mg/dl) 187 (31) 183 (27
LDL cholesterol (mg/dl) 109 (27) 105 (27
HDL cholesterol (mg/dl) 50 (9) 51 (12
Triglycerides (mg/dl) 161 (89) 159 (98
hs-CRP (mg/l) 4.2 (1.6–10.1) 3.3 (1.
OPG (pmol/l) 6.1 (4.2–10) 6 (4.*Difference between follow-up measurements in untreated and statin-treated
Abbreviations as in Table 1.ersely, those without CAC at baseline rarely showed
rogression (12%), even after adjusting for age. Regression
f CAC was rare, occurring in only 3%. All of the
raditional risk factors that were related to baseline calcifi-
ation remained predictive of CAC progression with the
xception of hyperlipidemia and smoking status. Notably,
erum HbA1c, IL-6, and OPG (although not hs-CRP)
ere univariable predictors of progression of CAC. Plasma
PG levels also correlated with atherosclerotic plaque
urden at follow-up. We found that statin therapy failed
o inhibit the progression of CAC. On the contrary, statin-
reated patients had a greater degree of progression. Similar
ndings were observed in patients treated with beta-blockers,
alcium channel antagonists, and angiotensin-converting en-
yme inhibitors/angiotensin receptor blockers.
Our findings are in accordance with published clinical
20) and experimental (21) studies that suggest that calcifi-
ation occurring in intimal atherosclerotic lesions might
tself induce further inflammation and calcification in a
ositive feedback loop, driving atherosclerotic disease pro-
ression. Our results also imply that subjects without CAC
t baseline do not need repeat studies in the short term. We
ave previously shown that such patients also have normal
yocardial perfusion and an excellent short-term prognosis
median follow-up  2.2 years). It is noteworthy that some
Figure 3 Multivariate Predictors
of Coronary Calcium Progression
Multivariate predictors of coronary calcium progression. Black squares denote
odds ratios, and the horizontal lines represent 95% confidence intervals. CAC
 coronary artery calcification; HbA1c  glycated hemoglobin.
rameters
ochemical Parameters
Statin Therapy (n  221)
p Value*Baseline Follow-Up
187 (27) 168 (35) 0.007
107 (31) 98 (27) 0.001
47 (10) 49 (16) 0.35
169 (89) 160 (108) 0.55
4 (1.9–7.6) 2.1 (1–5.1) 0.01
6.7 (4.7–10.5) 5.65 (4–7.9) 0.11al Pa
d Bi
177)
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)
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Determinants of CAC Progression in Diabetes December 4, 2007:2218–25raditional risk factors were related to incident CAC but not
rogression. It is possible that the lack of blinding of
atients to their baseline CAC scores might have affected
heir subsequent behavior (e.g., smoking), thus attenuating
isk relationships. An alternative explanation is that the
oronary calcium score reflects the lifetime coronary athero-
clerotic plaque burden, whereas progression of coronary
alcium score is a more proximate measure, reflecting
urrent disease activity. If true, this implies that serum
bA1c, IL-6, and plasma OPG levels are reflecting current
isease activity, consistent with current notions of the
iological roles of inflammation in atherogenesis.
PG and CAC. The findings of our study extend previous
vidence suggesting an association between elevated OPG
evels and vascular disease. Two previous prospective studies
howed the prognostic value of plasma OPG measurements
n asymptomatic subjects as well as post-myocardial infarc-
ion patients (13,22). Kiechl et al. (13) also showed that
PG was significantly related to the severity and 10-year
rogression of carotid atherosclerosis. Abedin et al. (23)
ecently demonstrated that plasma OPG levels were inde-
endently associated with CAC in an unselected popula-
ion. Together, these observations support the value of
PG in identifying patients with or at risk for vascular
isease.
revious studies of progression of CAC. Relatively few
tudies of progression of CAC have been published to date.
n 495 asymptomatic patients who underwent sequential
BCT studies, Raggi et al. (24) found that the risk of first
yocardial infarction was linked to progression of CAC. In
nother large (n  1,153) but retrospective study, they also
eported that diabetic patients with no coronary calcium on
aseline scans developed it more often than nondiabetic
ubjects during follow-up and that CAC progression was
reater in diabetic subjects than nondiabetic subjects, par-
icularly in the absence of statin therapy (4). Again, disease
rogression was significantly greater in those patients who
xperienced a myocardial infarction during follow-up.
The majority of studies evaluating progression of CAC
ave not been observational studies but have instead specif-
cally examined the impact of cholesterol levels and lipid-
owering therapy on progression of CAC. Conflicting re-
ults have been reported. An early, small (n  149)
etrospective study (25) linked the efficacy of lipid-lowering
reatment with change in volumetric CAC scores. A sub-
equent small prospective study (n  66) (26) showed that
rogression of CAC was inhibited at LDL cholesterol levels
130 mg/dl. In contrast, in a retrospective study by Yoon et
l. (20), LDL cholesterol levels were not predictive of CAC
rogression. In another prospective study of 661 patients,
ong et al. (27) reported that only high-density lipoprotein
holesterol (and not LDL cholesterol) was related to pro-
ression of CAC. The prospective multicenter EBEAT
EBCT Assessment of Coronary Calcification in High-
isk Patients with Minimal or Moderate Coronary Athero-
clerosis Receiving Intensive Lipid Lowering Atorvastatin pherapy) study (n  366) found no difference in progres-
ion of CAC in subjects receiving high-dose (80 mg) versus
tandard-dose (10 mg) atorvastatin (28). In a small random-
zed controlled trial of 102 patients with calcific aortic
tenosis and CAC, Houslay et al. (29) reported that
torvastatin failed to inhibit progression of CAC. Our
ndings are consistent with the aforementioned studies and
he prospective MESA (Multi-Ethnic Study of Atheroscle-
osis) published recently (30). The MESA also demon-
trated that lipid levels were related to baseline CAC but
ot its progression. In addition to the risk factors predictive
f CAC progression documented in our study, family
istory of CHD and white race/ethnicity were also predic-
ors in the MESA. It is worthwhile noting that MESA did
ot include any subjects of South Asian origin. It also had
larger sample size (n  5,756), which provides a greater
ower for identifying modest risk associations. Statin-
reated patients in the MESA had a greater progression of
oronary calcium, a finding similar to ours. There are several
ossible explanations for the lack of impact of medical
herapy on CAC progression. In general, patients receiving
edical therapy have a greater cardiovascular risk. In our
tudy, statin-treated patients had a greater baseline plaque
urden (median CAC 32 mm3, IQR 0 to 189) than
ntreated patients (median CAC 0 mm3, IQR 0 to 56),
upporting this notion. Alternatively, the aforementioned
esults might have been due to insufficient lowering of LDL
holesterol. The average LDL cholesterol level in statin-
reated patients in our study was 98 mg/dl, whereas in the
NT (Treating to New Targets) trial (31), the average
n-treatment LDL cholesterol in the intensively treated
rm was 77 mg/dl. Finally, data from animal experiments
ndicate that atherosclerotic calcification can increase in
xtent, especially in the initial stages of atherosclerotic
laque regression, due to fibrosis, foam cell necrosis, and
esultant calcification (32,33).
tudy limitations. Not all subjects who participated in the
nitial baseline study were subsequently enrolled in this
tudy (n  510 vs. n  402), either owing to cardiac
eath/coronary revascularization in the intervening period
r because they moved out of the area or declined the
nvitation. Neither subjects nor their physicians were
linded to their baseline CAC scores, which might have
nfluenced their subsequent behavior and treatment, as
iscussed previously. Because 54% of study patients were of
outh Asian origin, our findings might not necessarily be
eneralizable to other ethnic groups.
onclusions
e have documented the factors predicting progression of
AC (age, male gender, presence of hypertension, subop-
imal glycemic control, waist-hip ratio, serum IL-6, plasma
PG, baseline CAC score, and Framingham/UKPDS risk
cores) in asymptomatic type 2 diabetic subjects without
rior cardiovascular disease. Our study confirms that pro-
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December 4, 2007:2218–25 Determinants of CAC Progression in Diabetesression of CAC occurs mainly in persons with pre-existing
AC. Plasma OPG measurements were correlated with
aseline/follow-up CAC severity and predicted CAC pro-
ression. Further prospective studies evaluating the prog-
ostic value of CAC progression are necessary to establish
he usefulness of measuring CAC progression in asymp-
omatic diabetic subjects.
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